The "UAE In-Vitro Diagnostics Market - Growth, Trends & Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.
The growth of the UAE IVD market can be attributed to the high prevalence of chronic and infectious diseases.
Chronic diseases are a growing global challenge, and according to WHO estimates, account for approximately 60% of all deaths, worldwide. In addition, WHO states that chronic diseases, such as cancer, cardiovascular diseases, diabetes, and chronic respiratory diseases are responsible for 12%, 40%, 5%, and 5% of mortality in the United Arab Emirates.
The current market is also growing due to the use of advanced technologies in the IVD market. There has been a paradigm shift from traditional diagnostics to a new generation diagnostics, that works at the gene level. This was made possible by the inclusion of advanced technologies, such as genetic testing, molecular diagnostics, polymerase chain reaction (PCR), and next-generation sequencing (NGS).
Reagents Segment holds the Largest Market Share in the Product Type Segment
Reagents capture the largest market share and are expected to exhibit the fastest growth rate over the forecast period, owing to repeat purchase and increasing demand. The reagent segment of the market studied includes chemical, biological, or immunological components, solutions, and preparations intended by the manufacturer to be used during the in-vitro diagnostic process.
Given the high cost of many diagnostic platforms, it is common for manufacturers to lease equipment instead of selling technology outright to end users. In these arrangements, the lease is tied to contracts to purchase associated reagents or assay kits for the equipment over the life of the contract.
Many diagnostic companies have in excess of 75% of sales from consumables, such as assays and reagents, and such agreements guarantee the generation of cyclic revenues associated with the sale of reagents and other consumables. Reagent usage for IVD kits often carry high costs; hence, the availability of immunodiagnostic services in developing countries is often limited by the high cost of imported kits. Many developing countries have established local immunoassay reagent programs to manufacture low-cost, high-quality immunoassay reagents. Kits from these projects are now beginning to become available and are likely to fuel the market expansion.
The major market players in the UAE in-vitro diagnostics market are bioMerieux, Qiagen, Abbott Laboratories, Roche Diagnostics, and Siemens among others. The competition among manufacturers is increasing, with the increasing number of companies. Small manufacturers represent an unorganized market due to the lower prices of their products.
Key Topics Covered
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Dynamics
4.1 Market Overview
4.2 Market Drivers
4.2.1 High Prevalence of Chronic Diseases
4.2.2 Increasing Use of Point-of-care (POC) Diagnostics
4.2.3 Technological Advancements
4.2.4 Increasing Awareness & Acceptance of Personalized Medicine & Companion Diagnostics
4.3 Market Restraints
4.3.1 Stringent Regulations
4.3.2 Cumbersome Reimbursement Procedures
4.4 Porter's Five Forces Analysis
5 Market Segmentation
5.1 By Technique
5.1.2 POC Diagnostics
5.1.3 Molecular Diagnostics
5.1.5 Tissue Diagnostics
5.1.7 Self-blood Glucose Monitoring
5.1.8 Other Techniques
5.2 By Product
5.2.3 Data Management System
5.3 By Usablity
5.3.1 Disposable IVD Devices
5.3.2 Reusable IVD Devices
5.4 By Application
5.4.1 Infectious Disease
5.4.5 Autoimmune Disease
5.4.7 Drug Testing
5.4.9 Other Applications
5.5 End User
5.5.1 Laboratory & Academia
5.5.2 Hospitals and POC Testing Centers
5.5.3 Other End Users
6 Competitive Landscape
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Becton, Dickinson and Company
6.1.4 Bio-Rad Laboratories Inc.
6.1.5 Danaher Corporation
6.1.7 F. Hoffmann-La Roche Ltd.
6.1.8 Siemens Healthcare GmbH
6.1.9 Sysmex Corporation
6.1.10 Thermo Fisher Scientific
7 Market Opportunities and Future Trends
For more information about this report visit https://www.researchandmarkets.com/research/p38thz/uae_invitro?w=4
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: In Vitro Diagnostics